Skip to content

Study · Randomized controlled trial · n = 101 · 2025

2 results

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.

Apperloo EM, Gorriz JL, Soler MJ, Cigarrán Guldris S, Cruzado JM, Puchades MJ, López-Martínez M, Waanders F, Laverman GD, van der Aart-van der Beek A, Hoogenberg K, van Beek AP and 7 more

Show all authors

Verhave J, Ahmed SB, Schmieder RE, Wanner C, Cherney DZI, Jongs N, Heerspink HJL

Nature medicine25 Oct 2024Cited by 93 (Europe PMC)

PMID39455729 (opens in a new tab)DOI10.1038/s41591-024-03327-6 (opens in a new tab)PepBankPUB-39455729
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and non-diabetic chronic kidney disease, semaglutide 2.4 mg per week reduced UACR by 52.1% over 24 weeks versus placebo.

    In plain wordsIn adults with obesity and kidney disease without diabetes, semaglutide lowered urine albumin more than placebo over 24 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage change in UACR at week 24
    Study

    n = 101

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2.4 mg per week · 24 weeksAs given in this study (human).

    Measurements

    UACR change
    −52.1%
    semaglutide vs placebo

    Source sentences

    Summary
    Treatment for 24 weeks with semaglutide compared to placebo reduced UACR by -52.1% (95% confidence interval -65.5, -33.4; P < 0.0001).
    2 context sentences
    Summary · context
    We conducted a randomized placebo-controlled double-blind clinical trial in adults with CKD (estimated glomerular filtration rate (eGFR) ≥25 ml min-1 1.73 m-2 and urine albumin-to-creatinine ratio (UACR) ≥30 and -1) and body mass index ≥27 kg m<…
    Summary · context
    Participants were randomized to semaglutide 2.4 mg per week or placebo.
  2. 02HumanRandomized controlled trialSafety outcome

    In adults with overweight or obesity and non-diabetic chronic kidney disease, gastrointestinal adverse events were reported more often with semaglutide than with placebo.

    In plain wordsIn adults with obesity and kidney disease without diabetes, stomach and gut side effects were reported more often with semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n = 101

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mg per week · 24 weeksAs given in this study (human).

    Measurements

    Participants with GI adverse events
    30 participants
    semaglutide
    Participants with GI adverse events
    15 participants
    placebo

    Source sentences

    Summary
    Gastrointestinal adverse events were more often reported with semaglutide (n = 30) than with placebo (n = 15).
    2 context sentences
    Summary · context
    We conducted a randomized placebo-controlled double-blind clinical trial in adults with CKD (estimated glomerular filtration rate (eGFR) ≥25 ml min-1 1.73 m-2 and urine albumin-to-creatinine ratio (UACR) ≥30 and -1) and body mass index ≥27 kg m<…
    Summary · context
    Participants were randomized to semaglutide 2.4 mg per week or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT04889183

SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

University Medical Center Groningenn = 12514 Mar 2022 to 28 May 2024

Obesity · Albuminuria

Trial pageClinicalTrials.govUpdated 22 Apr 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.